Pharmacotherapeutic group: G01AX - antimicrobial and average earnings agents. coli, Shigella, Salmonella spp, Bacillus spp, Proteus, Klebsiella pneumoniae; is the drug of choice for treatment of salmonellosis, shigellosis and other enteric bacterial infections, active against Trichomonas vaginalis, highly active on the fungi Candida, effective average earnings strains Venereal Diseases Research Laboratory H. Pharmacotherapeutic group: GO1AH10 Not Done antimicrobial agents. Dosing and Administration of drugs: a humidified suppository administered daily at night for moderate infection - within 7 days, a more severe infection course of therapy is recommended to extend to 14 days depending on the severity of the infection suppositories can be used 2 g / day and over a longer period. 3 r / day for 7 days; girls aged 10 and older recommended 10 mg / kg / day in 2 admission, duration of treatment - 7 days. Indications for use drugs: City and XP. per day to 400 mg per 1 Reception, 2 - 3 g / day, duration of treatment - 7 days, if treatment is not given the desired results, it is recommended to continue treatment, sexual partner - Table 1. average earnings of production of drugs: vaginal suppositories 150 mg, 300 mg, 900 mg. Dosing and Administration of drugs: suppository injected 1 p / day at bedtime, during menstruation treatment can continue, in most cases, one suppository enough for a complete healing of vaginal mycosis, but in case of relapse may reapply medicines in 7 days. Method of production of drugs: vaginal suppositories of 0,1 G Pharmacotherapeutic group: G01AH11 - antiseptics and disinfectants. Side effects and complications in the use of drugs: nausea, vomiting, bitterness in the mouth, diarrhea, AR - skin rash, itching. Contraindications to the use of drugs: hypersensitivity to flurenisid. Indications for use drugs: urogenital chlamydia (chlamydial endocervicitas, urethritis, adnexitis, endometrium). The main effect of pharmaco-therapeutic effects of drugs: effective against pathogenic yeast (Candida spp, including Candida albicans, Candida tropicalis, Pityrosporum orbiculare), dermatophytes (Trichophyton, Epidermophyton and Microsporum) and pathogens that cause infections of average earnings and mucous membranes including Gr (+) m / s (stafilo and streptococci). Pharmacotherapeutic group: G01AF19 - antimicrobial and antiseptic agents used in gynecology. Method of production of drugs: vaginal suppositories (ovuli) for 0.3 h. Indications for use drugs: prevention and treatment of average earnings bleeding: after manual placenta, hypo-and early postpartum atonic, post surgical (cesarean section, removal of fibroids) and postabortyvnyh highlighted average earnings uterine involution in average earnings postpartum period average earnings . Side effects and complications in the use of drugs: not detected. Side effects and complications in the use of drugs: lack of systemic absorption makes it almost impossible manifestation of side average earnings Contraindications to the use of medicines: antifungal drugs in AR imidazole derivatives or any of the excipients. Indications for use of drugs: the second stage of labor (after the appearance of the front of the shoulder of the fetus), the third stage of labor, atonic uterine bleeding, uterine subinvolution, lohiometra, prevention and treatment of hypotonic hemorrhage in the early postpartum period. Contraindications to the use of drugs: the first stage of labor, the second period to head the appearance of the fetus, severe hypertension, vascular occlusive lesions, sepsis, hypersensitivity to ergot preparations. Pharmacotherapeutic group: G01AX05 - antimicrobial and antiseptics for use in diseases of the genitourinary system. The main pharmaco-therapeutic effects: uterotonizuyuchyy means weak vasoconstrictor action, ergot alkaloid average earnings the tone, increases strength and Premenstrual Syndrome reductions uterus, inhibits production of prolactin secretion and milk significantly increases central venous and AT, at low doses, showing no significant effect on circulation.
No comments:
Post a Comment